|Day Low/High||33.38 / 34.01|
|52 Wk Low/High||27.74 / 36.34|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: TWNK, VIRT Downgrades: AKAM, APLE, ATVI, BHE, BRFS, CAT, CCK, CDR, CUB, DIOD, DLHC, EXPE, GRA, GT, HCN, JNPR, NWSA, QGEN, REG, SEE, SUM, SXT, TRMB, UHAL, UNVR Initiations: ICHR Read on to get TheStreet Quant Ratings' detailed report:
New system launch planned for second half of 2018 with two CE-IVD molecular diagnostics, U.S. launch planned for 2019 and broad pipeline in development
Expanded use of ipsogen test provides diagnostic testing needs for all myeloproliferative neoplasms in line with the latest WHO guidelines
Extended labeling claim adds detection of three additional gene mutations to provide the most comprehensive mutation panel for GILOTRIF®
Investors in Qiagen NV saw new options begin trading this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Agreement includes payment of $27.5 million to Oxford, royalty free license to QIAGEN and dismissal of all pending litigation
Biomillenia, the developer of Smart Microbes™, announced today a collaboration with QIAGEN N.
First bioinformatics solution integrating new AMP/ASCO/CAP standards for NGS cancer testing to confidently and quickly report clinical relevance of somatic mutations
Studies at AMP 2017 demonstrate unique user experiences and high performance of new assays and workflows for multiple sample types
Outstanding and unmatched capabilities fuel strong growth in installed base and consumables use on highly versatile Sample to Insight automation solution
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMZN, CKH, GDDY, PRSC, QGEN, SHLM, VRX Downgrades: BRG, CZWI, FBP, HAIN, LNCE, PIH, TAIT, TPR, TTWO Initiations: ASIX, CWH Read on to get TheStreet Quant Ratings' detailed report:
Evaluation of clinical variant interpretation platform presented by Counsyl at ASHG 2017
Researchers at ASHG 2017 cite value of QIAGEN Sample to Insight solutions in multiple disease areas
Aiding the analysis of hereditary disorders by integrating genomic and clinical databases
Novel CD4/CD8 design delivers most comprehensive evaluation of patients' immune response to tuberculosis infection
Assuring the highest accuracy in human identity testing for law enforcement and other uses
Convenient blood test uses novel technology to test for recurrence of tumors by detecting circulating DNA
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.